Senior Medical Director, Early Clinical Development & Translational Medicine (MD) at Madrigal Pharmaceuticals in Conshohocken, PA

Job description

Madrigal is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease that can progress to cirrhosis, liver failure, need for liver transplantation and premature mortality. Every member of our Madrigal team is connected by our shared purpose: leading the fight against MASH. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). Our success is driven by our people. We are building a dynamic, inclusive, and high-performing culture that values scientific excellence, operational rigor, and collaboration. To support our continued growth, we are strengthening our workforce strategy to ensure we have the right talent, at the right time, in the right way. The Senior Medical Director, Early Clinical Development & Translational Medicine (MD ) is an experienced clinical development physician responsible for leading first-in-human and early-phase clinical programs and shaping translational strategy across Madrigal’s metabolic liver and cardiometabolic portfolio. This role requires substantial hands-on industry Clinical Development experience, including direct medical leadership of Phase 1 and early Phase 2 interventional studies. The individual will serve as medical lead and medical monitor for first-in-human, proof-of-concept, mechanistic, and indication-expansion studies, integrating clinical, biomarker, pharmacologic, and mechanistic data to inform dose selection, go/no-go decisions, subsequent development strategy, and lifecycle opportunities. The role will be a key member and often chair of early asset/program teams and a close partner to Research, Clinical Development, Clinical Pharmacology, Biostatistics, Regulatory Affairs, and Safety. Key Responsibilities Clinical Study Leadership Serve as global medical lead and medical monitor for early-phase interventional studies, including first-in-human, Phase 1/1b, early proof-of-concept, mechanistic, and indication-expansion trials in MASH and related cardiometabolic/liver conditions. Lead development of study concepts and protocols, including selection of patient populations, clinical and biomarker endpoints, dose-escalation/selection strategy, and mechanistic sub-studies. Provide hands-on medical oversight throughout study execution, including eligibility review, safety monitoring, dose decisions, benefit-risk assessment, and interpretation of emerging clinical data. Translate emerging clinical, safety, pharmacologic, and biomarker data into actionable program decisions and recommendations for subsequent development. Partner with Clinical Operations and CROs to ensure high-quality study execution, timely delivery of data, and inspection readiness. Translational and Biomarker Strategy Lead the clinical and translational strategy for assigned early-development programs, translating preclinical evidence into executable clinical development plans and integrating emerging human data to guide subsequent development. Integrate pharmacokinetic, pharmacodynamic, biomarker, imaging, and clinical outcome data to establish proof-of-mechanism, inform dose/regimen selection, and support development decisions. Integrate clinical biomarker strategy into early clinical development plans in close partnership with Research, Biomarkers, Clinical Pharmacology, and external laboratories/CROs. Guide biospecimen collection and downstream analyses to enable mechanistic understanding and future exploratory work. Cross-Functional Leadership and Governance Serve as the accountable physician and chair or co-chair early asset/program teams and translational